(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for th[...]
Read more
January 9, 2023
Column-Hedge fund petroleum buying paused over year end: Kemp
By John Kemp LONDON (Reuters) – Rallying oil prices ran out of steam just before the end of the year as investors turned cautious after two weeks of heavy petroleum buying. Hedge funds and other[...]
Read more
Ukraine expects EU to include Russia’s Rosatom in next sanctions
By Pavel Polityuk KYIV (Reuters) – Kyiv expects the European Union to include Russian state nuclear energy company Rosatom in its next round of sanctions over the war in Ukraine, Prime Minister[...]
Read more
South Africa’s Eskom says police investigating alleged poisoning of CEO
By Wendell Roelf CAPE TOWN (Reuters) -South African power utility Eskom on Sunday said police were investigating whether an attempt was made to poison its outgoing Chief Executive Officer Andre de Ruy[...]
Read more
Factbox-The 10 biggest U.S. retail bankruptcies in 5 years
NEW YORK (Reuters) – Storied home goods chain Bed Bath & Beyond is preparing for bankruptcy in coming weeks following a run of poor sales, sources told Reuters last week. A bankruptcy would[...]
Read more
Credit Suisse nears deal to buy Michael Klein’s advisory firm – Bloomberg News
(Reuters) – Credit Suisse Group AG is close to an agreement to acquire former Citigroup executive Michael Klein’s advisory boutique, Bloomberg News reported on Monday. The Swiss bank will[...]
Read more
Brazil’s soybean harvest off to slow start -AgRural
SAO PAULO (Reuters) – Harvesting of Brazil’s 2022/2023 soybean crop had reached 0.04% of the national planted area on Thursday last week, compared with 0.2% at the same time a year earlier[...]
Read more
AstraZeneca boosts heart, kidney business with $1.8 billion CinCor deal
By Natalie Grover (Reuters) -AstraZeneca said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc for up to $1.8 billion to increase its stock of heart and kidney drugs.[...]
Read more
Private equity acquires a taste for drug development
By David Carnevali (Reuters) – Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and comi[...]
Read more